Publications

Here, we provide an update to our letter to the editor of a patient with KIF5B-RET–positive NSCLC who developed acquired MET amplification after treatment with selpercatinib on expanded access. We switched the patient to cabozantinib, a multitargeted MET and RET tyrosine kinase inhibitor (TKI), at 40 mg once daily together with four cycles of carboplatin, pemetrexed, and bevacizumab combination chemotherapy.